Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group
A Sulkes, J Smyth, C Sessa, L Y Dirix, J B Vermorken, S Kaye, J Wanders, H Franklin, N LeBail, J Verweij, A Sulkes, J Smyth, C Sessa, L Y Dirix, J B Vermorken, S Kaye, J Wanders, H Franklin, N LeBail, J Verweij
Abstract
Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11+). An additional 11 patients had stabilisation of disease. The patients received a median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) l-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted.
References
- Ann Intern Med. 1980 Oct;93(4):533-6
- CA Cancer J Clin. 1985 Jan-Feb;35(1):19-35
- J Clin Oncol. 1986 Dec;4(12):1799-803
- Isr J Med Sci. 1988 Sep-Oct;24(9-10):557-61
- Oncology. 1989;46(2):83-7
- J Clin Oncol. 1990 May;8(5):939-41
- J Med Chem. 1991 Mar;34(3):992-8
- Cancer Res. 1991 Sep 15;51(18):4845-52
- Eur J Cancer. 1991;27(10):1238-42
- J Clin Oncol. 1993 May;11(5):950-8
Source: PubMed